Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/1471-2407-10-108.

Title:
The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence | BMC Cancer
Description:
Background Over-expression of HER2 in a subset of breast cancers (HER2+) is associated with high histological grade and aggressive clinical course. Despite these distinctive features, the differences in response of HER2+ patients to both adjuvant cytotoxic chemotherapy and targeted therapy (e.g. trastuzumab) suggests that unrecognized biologic and clinical diversity is confounding treatment strategies. Furthermore, the small but established risk of cardiac morbidity with trastuzumab therapy compels efforts towards the identification of biomarkers that might help stratify patients. Methods A single institution tissue array cohort assembled at the Clearview Cancer Institute of Huntsville (CCIH) was screened by immunohistochemistry staining using a large number of novel and commercially available antibodies to identify those with a univariate association with clinical outcome in HER2+ patients. Staining with antibody directed at TRMT2A was found to be strongly associated with outcome in HER2+ patients. This association with outcome was tested in two independent validation cohorts; an existing staining dataset derived from tissue assembled at the Cleveland Clinic Foundation (CCF), and in a new retrospective study performed by staining archived paraffin blocks available at the Roswell Park Cancer Institute (RPCI). Results TRMT2A staining showed a strong correlation with likelihood of recurrence at five years in 67 HER2+ patients from the CCIH discovery cohort (HR 7.0; 95% CI 2.4 to 20.1, p < 0.0004). This association with outcome was confirmed using 75 HER2+ patients from the CCF cohort (HR 3.6; 95% CI 1.3 to 10.2, p < 0.02) and 64 patients from the RPCI cohort (HR 3.4; 95% CI 1.3-8.9, p < 0.02). In bivariable analysis the association with outcome was independent of grade, tumor size, nodal status and the administration of conventional adjuvant chemotherapy in the CCIH and RPCI cohorts. Conclusions Studies from three independent single institution cohorts support TRMT2A protein expression as a biomarker of increased risk of recurrence in HER2+ breast cancer patients. These results suggest that TRMT2A expression should be further studied in the clinical trial setting to explore its predictive power for response to adjuvant cytotoxic chemotherapy in combination with HER2 targeted therapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {๐Ÿ“š}

  • Education
  • Science
  • Health & Fitness

Content Management System {๐Ÿ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {๐Ÿ“ˆ}

What is the average monthly size of link.springer.com audience?

๐ŸŒ  Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {๐Ÿ’ธ}

The income method remains a mystery to us.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {๐Ÿ”}

cancer, patients, breast, trmta, clinical, staining, article, expression, outcome, cohort, pubmed, antibody, independent, cohorts, google, scholar, ccih, tumor, cas, adjuvant, trastuzumab, association, data, ccf, study, chemotherapy, therapy, monoclonal, cell, recurrence, rpci, receptor, protein, treatment, positive, cases, tissue, antibodies, directed, figure, analysis, prognostic, table, polyclonal, risk, size, gene, clin, targeted, assembled,

Topics {โœ’๏ธ}

double-stranded dna-binding factors pre-publication history her2-positive breast cancer open access article article download pdf her2+/trmt2a+ breast cancers polyclonal affinity-purified antibodies full size image individualizing curative-intent therapy tissue array sections aid clinical decision-making rabbit monoclonal antibody human breast cancer ccih tissue array[16] breast cancer cases ccf tissue arrays breast cancer specimens progesterone receptor expression metastatic breast cancer archived tumor samples breast cancer patients clin breast cancer clearview cancer institute cox proportional hazards er+ breast cancer privacy choices/manage cookies open reading frame human breast tumours authorsโ€™ original file bmc cancer 10 thaer khouryย &ย daniel dim original polyclonal antibody gene expression patterns breast tumor classification[16] breast tumor subtypes full access clin cancer res her2 positive cohort slamon dj regulate dna replication hormone receptor status estrogen receptor expression estrogen receptor alpha molecular alteration carries biomed central human cell cycle her2 positive tumors her2 positive tumors[5 emerging targeted therapies her2 positive patients

Questions {โ“}

  • Brenton JD, Carey LA, Ahmed AA, Caldas C: Molecular classification and molecular forecasting of breast cancer: ready for clinical application?

Schema {๐Ÿ—บ๏ธ}

WebPage:
      mainEntity:
         headline:The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence
         description:Over-expression of HER2 in a subset of breast cancers (HER2+) is associated with high histological grade and aggressive clinical course. Despite these distinctive features, the differences in response of HER2+ patients to both adjuvant cytotoxic chemotherapy and targeted therapy (e.g. trastuzumab) suggests that unrecognized biologic and clinical diversity is confounding treatment strategies. Furthermore, the small but established risk of cardiac morbidity with trastuzumab therapy compels efforts towards the identification of biomarkers that might help stratify patients. A single institution tissue array cohort assembled at the Clearview Cancer Institute of Huntsville (CCIH) was screened by immunohistochemistry staining using a large number of novel and commercially available antibodies to identify those with a univariate association with clinical outcome in HER2+ patients. Staining with antibody directed at TRMT2A was found to be strongly associated with outcome in HER2+ patients. This association with outcome was tested in two independent validation cohorts; an existing staining dataset derived from tissue assembled at the Cleveland Clinic Foundation (CCF), and in a new retrospective study performed by staining archived paraffin blocks available at the Roswell Park Cancer Institute (RPCI). TRMT2A staining showed a strong correlation with likelihood of recurrence at five years in 67 HER2+ patients from the CCIH discovery cohort (HR 7.0; 95% CI 2.4 to 20.1, p &lt; 0.0004). This association with outcome was confirmed using 75 HER2+ patients from the CCF cohort (HR 3.6; 95% CI 1.3 to 10.2, p &lt; 0.02) and 64 patients from the RPCI cohort (HR 3.4; 95% CI 1.3-8.9, p &lt; 0.02). In bivariable analysis the association with outcome was independent of grade, tumor size, nodal status and the administration of conventional adjuvant chemotherapy in the CCIH and RPCI cohorts. Studies from three independent single institution cohorts support TRMT2A protein expression as a biomarker of increased risk of recurrence in HER2+ breast cancer patients. These results suggest that TRMT2A expression should be further studied in the clinical trial setting to explore its predictive power for response to adjuvant cytotoxic chemotherapy in combination with HER2 targeted therapy.
         datePublished:2010-03-22T00:00:00Z
         dateModified:2010-03-22T00:00:00Z
         pageStart:1
         pageEnd:7
         license:https://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1471-2407-10-108
         keywords:
            Breast Cancer
            Trastuzumab
            Tissue Array
            Rabbit Monoclonal Antibody
            Progesterone Receptor Expression
            Cancer Research
            Oncology
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-10-108/MediaObjects/12885_2009_Article_1907_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-10-108/MediaObjects/12885_2009_Article_1907_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-10-108/MediaObjects/12885_2009_Article_1907_Fig3_HTML.jpg
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:10
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:David G Hicks
               affiliation:
                     name:University of Rochester
                     address:
                        name:University of Rochester, Rochester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bagi R Janarthanan
               affiliation:
                     name:University of Rochester
                     address:
                        name:University of Rochester, Rochester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ramya Vardarajan
               affiliation:
                     name:University of Rochester
                     address:
                        name:University of Rochester, Rochester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Swati A Kulkarni
               affiliation:
                     name:University of Rochester
                     address:
                        name:University of Rochester, Rochester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thaer Khoury
               affiliation:
                     name:University of Rochester
                     address:
                        name:University of Rochester, Rochester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Daniel Dim
               affiliation:
                     name:University of Rochester
                     address:
                        name:University of Rochester, Rochester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:G Thomas Budd
               affiliation:
                     name:The Cleveland Clinic Foundation
                     address:
                        name:The Cleveland Clinic Foundation, Cleveland, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Brian J Yoder
               affiliation:
                     name:The Cleveland Clinic Foundation
                     address:
                        name:The Cleveland Clinic Foundation, Cleveland, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Raymond Tubbs
               affiliation:
                     name:The Cleveland Clinic Foundation
                     address:
                        name:The Cleveland Clinic Foundation, Cleveland, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marshall T Schreeder
               affiliation:
                     name:Clearview Cancer Center
                     address:
                        name:Clearview Cancer Center, Huntsville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Noel C Estopinal
               affiliation:
                     name:Clearview Cancer Center
                     address:
                        name:Clearview Cancer Center, Huntsville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rodney A Beck
               affiliation:
                     name:Clarient Inc
                     address:
                        name:Clarient Inc, Huntsville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yanling Wang
               affiliation:
                     name:Clarient Inc
                     address:
                        name:Clarient Inc, Aliso Veijo, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Brian Z Ring
               affiliation:
                     name:Clarient Inc
                     address:
                        name:Clarient Inc, Aliso Veijo, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robert S Seitz
               affiliation:
                     name:Clarient Inc
                     address:
                        name:Clarient Inc, Huntsville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Douglas T Ross
               affiliation:
                     name:Clarient Inc
                     address:
                        name:Clarient Inc, Aliso Veijo, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence
      description:Over-expression of HER2 in a subset of breast cancers (HER2+) is associated with high histological grade and aggressive clinical course. Despite these distinctive features, the differences in response of HER2+ patients to both adjuvant cytotoxic chemotherapy and targeted therapy (e.g. trastuzumab) suggests that unrecognized biologic and clinical diversity is confounding treatment strategies. Furthermore, the small but established risk of cardiac morbidity with trastuzumab therapy compels efforts towards the identification of biomarkers that might help stratify patients. A single institution tissue array cohort assembled at the Clearview Cancer Institute of Huntsville (CCIH) was screened by immunohistochemistry staining using a large number of novel and commercially available antibodies to identify those with a univariate association with clinical outcome in HER2+ patients. Staining with antibody directed at TRMT2A was found to be strongly associated with outcome in HER2+ patients. This association with outcome was tested in two independent validation cohorts; an existing staining dataset derived from tissue assembled at the Cleveland Clinic Foundation (CCF), and in a new retrospective study performed by staining archived paraffin blocks available at the Roswell Park Cancer Institute (RPCI). TRMT2A staining showed a strong correlation with likelihood of recurrence at five years in 67 HER2+ patients from the CCIH discovery cohort (HR 7.0; 95% CI 2.4 to 20.1, p &lt; 0.0004). This association with outcome was confirmed using 75 HER2+ patients from the CCF cohort (HR 3.6; 95% CI 1.3 to 10.2, p &lt; 0.02) and 64 patients from the RPCI cohort (HR 3.4; 95% CI 1.3-8.9, p &lt; 0.02). In bivariable analysis the association with outcome was independent of grade, tumor size, nodal status and the administration of conventional adjuvant chemotherapy in the CCIH and RPCI cohorts. Studies from three independent single institution cohorts support TRMT2A protein expression as a biomarker of increased risk of recurrence in HER2+ breast cancer patients. These results suggest that TRMT2A expression should be further studied in the clinical trial setting to explore its predictive power for response to adjuvant cytotoxic chemotherapy in combination with HER2 targeted therapy.
      datePublished:2010-03-22T00:00:00Z
      dateModified:2010-03-22T00:00:00Z
      pageStart:1
      pageEnd:7
      license:https://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1471-2407-10-108
      keywords:
         Breast Cancer
         Trastuzumab
         Tissue Array
         Rabbit Monoclonal Antibody
         Progesterone Receptor Expression
         Cancer Research
         Oncology
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-10-108/MediaObjects/12885_2009_Article_1907_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-10-108/MediaObjects/12885_2009_Article_1907_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-10-108/MediaObjects/12885_2009_Article_1907_Fig3_HTML.jpg
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:10
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:David G Hicks
            affiliation:
                  name:University of Rochester
                  address:
                     name:University of Rochester, Rochester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bagi R Janarthanan
            affiliation:
                  name:University of Rochester
                  address:
                     name:University of Rochester, Rochester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ramya Vardarajan
            affiliation:
                  name:University of Rochester
                  address:
                     name:University of Rochester, Rochester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Swati A Kulkarni
            affiliation:
                  name:University of Rochester
                  address:
                     name:University of Rochester, Rochester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thaer Khoury
            affiliation:
                  name:University of Rochester
                  address:
                     name:University of Rochester, Rochester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Daniel Dim
            affiliation:
                  name:University of Rochester
                  address:
                     name:University of Rochester, Rochester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:G Thomas Budd
            affiliation:
                  name:The Cleveland Clinic Foundation
                  address:
                     name:The Cleveland Clinic Foundation, Cleveland, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Brian J Yoder
            affiliation:
                  name:The Cleveland Clinic Foundation
                  address:
                     name:The Cleveland Clinic Foundation, Cleveland, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Raymond Tubbs
            affiliation:
                  name:The Cleveland Clinic Foundation
                  address:
                     name:The Cleveland Clinic Foundation, Cleveland, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marshall T Schreeder
            affiliation:
                  name:Clearview Cancer Center
                  address:
                     name:Clearview Cancer Center, Huntsville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Noel C Estopinal
            affiliation:
                  name:Clearview Cancer Center
                  address:
                     name:Clearview Cancer Center, Huntsville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rodney A Beck
            affiliation:
                  name:Clarient Inc
                  address:
                     name:Clarient Inc, Huntsville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yanling Wang
            affiliation:
                  name:Clarient Inc
                  address:
                     name:Clarient Inc, Aliso Veijo, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Brian Z Ring
            affiliation:
                  name:Clarient Inc
                  address:
                     name:Clarient Inc, Aliso Veijo, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robert S Seitz
            affiliation:
                  name:Clarient Inc
                  address:
                     name:Clarient Inc, Huntsville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Douglas T Ross
            affiliation:
                  name:Clarient Inc
                  address:
                     name:Clarient Inc, Aliso Veijo, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:10
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Rochester
      address:
         name:University of Rochester, Rochester, USA
         type:PostalAddress
      name:University of Rochester
      address:
         name:University of Rochester, Rochester, USA
         type:PostalAddress
      name:University of Rochester
      address:
         name:University of Rochester, Rochester, USA
         type:PostalAddress
      name:University of Rochester
      address:
         name:University of Rochester, Rochester, USA
         type:PostalAddress
      name:University of Rochester
      address:
         name:University of Rochester, Rochester, USA
         type:PostalAddress
      name:University of Rochester
      address:
         name:University of Rochester, Rochester, USA
         type:PostalAddress
      name:The Cleveland Clinic Foundation
      address:
         name:The Cleveland Clinic Foundation, Cleveland, USA
         type:PostalAddress
      name:The Cleveland Clinic Foundation
      address:
         name:The Cleveland Clinic Foundation, Cleveland, USA
         type:PostalAddress
      name:The Cleveland Clinic Foundation
      address:
         name:The Cleveland Clinic Foundation, Cleveland, USA
         type:PostalAddress
      name:Clearview Cancer Center
      address:
         name:Clearview Cancer Center, Huntsville, USA
         type:PostalAddress
      name:Clearview Cancer Center
      address:
         name:Clearview Cancer Center, Huntsville, USA
         type:PostalAddress
      name:Clarient Inc
      address:
         name:Clarient Inc, Huntsville, USA
         type:PostalAddress
      name:Clarient Inc
      address:
         name:Clarient Inc, Aliso Veijo, USA
         type:PostalAddress
      name:Clarient Inc
      address:
         name:Clarient Inc, Aliso Veijo, USA
         type:PostalAddress
      name:Clarient Inc
      address:
         name:Clarient Inc, Huntsville, USA
         type:PostalAddress
      name:Clarient Inc
      address:
         name:Clarient Inc, Aliso Veijo, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:David G Hicks
      affiliation:
            name:University of Rochester
            address:
               name:University of Rochester, Rochester, USA
               type:PostalAddress
            type:Organization
      name:Bagi R Janarthanan
      affiliation:
            name:University of Rochester
            address:
               name:University of Rochester, Rochester, USA
               type:PostalAddress
            type:Organization
      name:Ramya Vardarajan
      affiliation:
            name:University of Rochester
            address:
               name:University of Rochester, Rochester, USA
               type:PostalAddress
            type:Organization
      name:Swati A Kulkarni
      affiliation:
            name:University of Rochester
            address:
               name:University of Rochester, Rochester, USA
               type:PostalAddress
            type:Organization
      name:Thaer Khoury
      affiliation:
            name:University of Rochester
            address:
               name:University of Rochester, Rochester, USA
               type:PostalAddress
            type:Organization
      name:Daniel Dim
      affiliation:
            name:University of Rochester
            address:
               name:University of Rochester, Rochester, USA
               type:PostalAddress
            type:Organization
      name:G Thomas Budd
      affiliation:
            name:The Cleveland Clinic Foundation
            address:
               name:The Cleveland Clinic Foundation, Cleveland, USA
               type:PostalAddress
            type:Organization
      name:Brian J Yoder
      affiliation:
            name:The Cleveland Clinic Foundation
            address:
               name:The Cleveland Clinic Foundation, Cleveland, USA
               type:PostalAddress
            type:Organization
      name:Raymond Tubbs
      affiliation:
            name:The Cleveland Clinic Foundation
            address:
               name:The Cleveland Clinic Foundation, Cleveland, USA
               type:PostalAddress
            type:Organization
      name:Marshall T Schreeder
      affiliation:
            name:Clearview Cancer Center
            address:
               name:Clearview Cancer Center, Huntsville, USA
               type:PostalAddress
            type:Organization
      name:Noel C Estopinal
      affiliation:
            name:Clearview Cancer Center
            address:
               name:Clearview Cancer Center, Huntsville, USA
               type:PostalAddress
            type:Organization
      name:Rodney A Beck
      affiliation:
            name:Clarient Inc
            address:
               name:Clarient Inc, Huntsville, USA
               type:PostalAddress
            type:Organization
      name:Yanling Wang
      affiliation:
            name:Clarient Inc
            address:
               name:Clarient Inc, Aliso Veijo, USA
               type:PostalAddress
            type:Organization
      name:Brian Z Ring
      affiliation:
            name:Clarient Inc
            address:
               name:Clarient Inc, Aliso Veijo, USA
               type:PostalAddress
            type:Organization
      name:Robert S Seitz
      affiliation:
            name:Clarient Inc
            address:
               name:Clarient Inc, Huntsville, USA
               type:PostalAddress
            type:Organization
      name:Douglas T Ross
      affiliation:
            name:Clarient Inc
            address:
               name:Clarient Inc, Aliso Veijo, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:University of Rochester, Rochester, USA
      name:University of Rochester, Rochester, USA
      name:University of Rochester, Rochester, USA
      name:University of Rochester, Rochester, USA
      name:University of Rochester, Rochester, USA
      name:University of Rochester, Rochester, USA
      name:The Cleveland Clinic Foundation, Cleveland, USA
      name:The Cleveland Clinic Foundation, Cleveland, USA
      name:The Cleveland Clinic Foundation, Cleveland, USA
      name:Clearview Cancer Center, Huntsville, USA
      name:Clearview Cancer Center, Huntsville, USA
      name:Clarient Inc, Huntsville, USA
      name:Clarient Inc, Aliso Veijo, USA
      name:Clarient Inc, Aliso Veijo, USA
      name:Clarient Inc, Huntsville, USA
      name:Clarient Inc, Aliso Veijo, USA

External Links {๐Ÿ”—}(124)

Analytics and Tracking {๐Ÿ“Š}

  • Google Tag Manager

Libraries {๐Ÿ“š}

  • Clipboard.js
  • Prism.js

CDN Services {๐Ÿ“ฆ}

  • Crossref

4.85s.